Incidence trends and survival analysis of appendiceal tumors in the United States: Primarily changes in appendiceal neuroendocrine tumors.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
08
2023
accepted:
25
10
2023
medline:
15
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
Appendiceal tumors are considered to be a relatively rare tumor of the gastrointestinal tract and the prognosis is unclear. This study comprehensively investigated trends in the epidemiology and survival of appendiceal tumors in the United States over the past approximately 20 years. Patients with pathologically confirmed appendiceal tumors from 2000 to 2017 were selected from the Surveillance, Epidemiology and End Results (SEER) database. Age-adjusted incidence rates were calculated by SEER*Stat 8.4.0. The Kaplan-Meier method was used to analyze survival and prognostic factors were investigated by a multivariate Cox proportional risk model. Ultimately, 13,546 patients with appendiceal tumors between 2000 and 2017 were included. The annual incidence of colonic adenocarcinoma and mucinous adenocarcinoma remained relatively stable. Interestingly, the annual incidence of appendiceal neuroendocrine tumors (aNETs) increased significantly, from 0.03 to 0.90 per 100,000 person-years, with the most dramatic increase in the number of patients with localized disease. Patients with aNETs showed a significant improvement in survival between 2009-2017, compared to the period 2000-2008. Moreover, this improvement in survival over time was seen at all stages (localized, regional, distant) of aNETs. However, this improved survival over time was not seen in colonic and mucinous adenocarcinoma. The incidence of appendiceal neoplasms has increased significantly over the past nearly two decades, which is mainly due to the increased incidence and significant migration to earlier stages in aNETs. We must note that despite the increased incidence of aNETs, survival rates have improved at different disease stages.
Sections du résumé
BACKGROUND
Appendiceal tumors are considered to be a relatively rare tumor of the gastrointestinal tract and the prognosis is unclear. This study comprehensively investigated trends in the epidemiology and survival of appendiceal tumors in the United States over the past approximately 20 years.
METHODS
Patients with pathologically confirmed appendiceal tumors from 2000 to 2017 were selected from the Surveillance, Epidemiology and End Results (SEER) database. Age-adjusted incidence rates were calculated by SEER*Stat 8.4.0. The Kaplan-Meier method was used to analyze survival and prognostic factors were investigated by a multivariate Cox proportional risk model.
RESULTS
Ultimately, 13,546 patients with appendiceal tumors between 2000 and 2017 were included. The annual incidence of colonic adenocarcinoma and mucinous adenocarcinoma remained relatively stable. Interestingly, the annual incidence of appendiceal neuroendocrine tumors (aNETs) increased significantly, from 0.03 to 0.90 per 100,000 person-years, with the most dramatic increase in the number of patients with localized disease. Patients with aNETs showed a significant improvement in survival between 2009-2017, compared to the period 2000-2008. Moreover, this improvement in survival over time was seen at all stages (localized, regional, distant) of aNETs. However, this improved survival over time was not seen in colonic and mucinous adenocarcinoma.
CONCLUSIONS
The incidence of appendiceal neoplasms has increased significantly over the past nearly two decades, which is mainly due to the increased incidence and significant migration to earlier stages in aNETs. We must note that despite the increased incidence of aNETs, survival rates have improved at different disease stages.
Identifiants
pubmed: 37956190
doi: 10.1371/journal.pone.0294153
pii: PONE-D-23-24612
pmc: PMC10642837
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0294153Informations de copyright
Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Interv Aging. 2021 Mar 30;16:559-568
pubmed: 33833505
J Invest Surg. 2021 Aug;34(8):924-930
pubmed: 31931634
Front Oncol. 2022 Jan 31;12:799930
pubmed: 35174085
Endocr Relat Cancer. 2016 Jan;23(1):R27-41
pubmed: 26483424
Cancers (Basel). 2022 Dec 31;15(1):
pubmed: 36612291
J Clin Oncol. 2009 Oct 1;27(28):4656-63
pubmed: 19704057
Cochrane Database Syst Rev. 2021 Nov 25;11:CD013700
pubmed: 34822169
Oncologist. 2017 Sep;22(9):1107-1116
pubmed: 28663356
Int J Colorectal Dis. 2013 Sep;28(9):1307-10
pubmed: 23695388
Pancreas. 2010 Aug;39(6):753-66
pubmed: 20664473
Cancer. 2020 May 15;126(10):2206-2216
pubmed: 32101643
Expert Rev Gastroenterol Hepatol. 2017 Mar;11(3):237-247
pubmed: 28081662
World J Gastrointest Oncol. 2020 Aug 15;12(8):791-807
pubmed: 32879660
Clin Colon Rectal Surg. 2015 Dec;28(4):247-55
pubmed: 26648795
Therap Adv Gastroenterol. 2017 Jan;10(1):132-141
pubmed: 28286565
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Endocr Pathol. 2022 Mar;33(1):115-154
pubmed: 35294740
Eur J Surg Oncol. 2015 Sep;41(9):1243-6
pubmed: 26188371
Front Oncol. 2023 Jan 26;13:1079575
pubmed: 36776304
Contemp Oncol (Pozn). 2015;19(5):345-9
pubmed: 26793016
Oncologist. 2022 Jul 5;27(7):573-578
pubmed: 35348774
Pancreas. 2010 Aug;39(6):767-74
pubmed: 20664474
Lancet. 2011 Dec 10;378(9808):2005-2012
pubmed: 22119496
J Surg Oncol. 2019 Sep;120(4):736-739
pubmed: 31309554
J Am Coll Surg. 2022 Jun 1;234(6):1082-1089
pubmed: 35703801
Dis Colon Rectum. 2019 Dec;62(12):1425-1438
pubmed: 31725580
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Cancer. 2016 Jan 15;122(2):213-21
pubmed: 26506400
Minerva Endocrinol. 2020 Dec;45(4):381-392
pubmed: 32720498
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
Neuroendocrinology. 2008;87(1):20-30
pubmed: 17934252
J Surg Oncol. 2005 Mar 1;89(3):151-60
pubmed: 15719376